Cargando…
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent therapeutic is necessary. Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase...
Autores principales: | Yamaue, Hiroki, Tsunoda, Takuya, Tani, Masaji, Miyazawa, Motoki, Yamao, Kenji, Mizuno, Nobumasa, Okusaka, Takuji, Ueno, Hideki, Boku, Narikazu, Fukutomi, Akira, Ishii, Hiroshi, Ohkawa, Shinichi, Furukawa, Masayuki, Maguchi, Hiroyuki, Ikeda, Masafumi, Togashi, Yosuke, Nishio, Kazuto, Ohashi, Yasuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520640/ https://www.ncbi.nlm.nih.gov/pubmed/25867139 http://dx.doi.org/10.1111/cas.12674 |
Ejemplares similares
-
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
por: Matsuyama, Masato, et al.
Publicado: (2014) -
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015) -
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014) -
Identification of HLA-A24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20A
por: Osawa, Ryuji, et al.
Publicado: (2012) -
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)